Plain-English translation of NCT07549412 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 3 β Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called to see if it can help people with advanced colorectal cancer that has progressed despite previous treatments. You would receive this medication either by itself or combined with (a drug that helps block cancer growth), and your outcomes would be compared to people receiving the current standard treatment, which is trifluridine/tipiracil plus .
Many people with advanced colorectal cancer eventually stop responding to standard treatments and have limited options left. This trial exists to see whether this new medication might help extend survival and give patients who have exhausted other options another fighting chance.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
You would be randomly assigned to one of three groups: taking the new medication alone, taking the new medication combined with , or taking the standard treatment combination. You would take oral tablets and visit the clinic regularly for checkups, blood tests, and scans to monitor how well the treatment is working and any side effects you experience. The study will continue until there is enough information to know which treatment approach helps people live longer.
AI-generated summary from trial data Β· Jun 23, 2026 Β· Not medical advice
United States